Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Praxis Precision Medicines, Inc. PRAX
$1.04
-$0.03 (-2.80%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
54488824.00000000
-
week52high
13.33
-
week52low
0.79
-
Revenue
0
-
P/E TTM
0
-
Beta
3.00727300
-
EPS
-5.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 08 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 июн 2022 г. |
| B of A Securities | Neutral | Buy | 07 июн 2022 г. |
| HC Wainwright & Co. | Buy | 16 дек 2021 г. | |
| B of A Securities | Buy | 26 авг 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Nemiroff Alex | A | 120000 | 120000 | 12 янв 2023 г. |
| Souza Marcio | A | 425000 | 425000 | 12 янв 2023 г. |
| Souza Marcio | A | 213975 | 213975 | 12 янв 2023 г. |
| Kelly Timothy Edwin | A | 42455 | 42455 | 12 янв 2023 г. |
| Nemiroff Alex | A | 36520 | 36520 | 12 янв 2023 г. |
| Mastrocola Lauren | A | 3110 | 3110 | 12 янв 2023 г. |
| Sweeny Nicole | A | 41085 | 41085 | 12 янв 2023 г. |
| Kelly Timothy Edwin | A | 150000 | 150000 | 12 янв 2023 г. |
| Sweeny Nicole | A | 120000 | 120000 | 12 янв 2023 г. |
| Mastrocola Lauren | A | 50000 | 50000 | 12 янв 2023 г. |
Новостная лента
Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
GlobeNewsWire
28 ноя 2022 г. в 16:05
BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee.
Praxis Precision Medicines to Present at Upcoming Investor Conferences
GlobeNewsWire
07 ноя 2022 г. в 09:00
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:
Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference
GlobeNewsWire
21 сент 2022 г. в 09:00
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Wednesday, September 28, 2022 at 11:45 a.m. ET.
Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
07 сент 2022 г. в 16:05
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 10:30 a.m. ET.
Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Seeking Alpha
10 июн 2022 г. в 14:45
A phase 2/3 trial failure in the MDD indication of PRAX-114 allows this biotech to shift focus over to PRAX-944 for Essential tremors and other preclinical drugs. Results from the phase 2b Essential1 study using PRAX-944 for treatment of patients with essential tremors expected 2nd half of 2022; preliminary results already released from phase 2a study.